Proliferating activity in differential diagnosis of benign phyllodes tumor and cellular fibroadenomas: Is it helpful?

Role of proliferative markers in breast lesions

“…Cystosarcoma phylloides showed PCNA LI of 22-25% with a mean of 23.3%. In the study conducted by Kayr et al the PCNA LI of stromal cells in these tumors were 28.01 + 22.85 which was slightly more than our fi ndings [7]. The only case of lactating adenoma showed PCNA LI range of 3-4 and a mean of 3.5%.…”

Expression of anaphase-promoting complex7 in fibroadenomas and phyllodes tumors of breast

“…We found juvenile FAs with higher Ki-67 indices than some of the benign PTs. This result is consistent with the results of previous studies [7,19]. In addition, lower Ki-67 labeling indices in both FA groups (mean, 0.51% ± 0.87%) and benign PTs (mean, 1.77% ± 2.35%) may not be helpful in small biopsied specimens.…”

Immunohistochemical expression of Ki-67, p53, and CD10 in phyllodes tumor and their correlation with its histological grade

“…[11] In the study by Kaya et al, proliferating cell nuclear antigen and Ki-67 immunostaining did not reveal significant differences between PT and fibroadenoma. [5] Ki-67, p53 and c-kit have been reported to be useful by some authors in distinguishing benign from malignant PT in diagnostically difficult cases. However, only c-kit was found useful in predicting recurrences in PT.…”

“…This frequency of malignant progression has been reported to be 5%-30% of all PT by various studies. [5] Histologically, PTs are divided into three subgroups: benign, borderline, and malignant. This classification reflects their clinic-pathological behavior and is based on the following histological criteria: (i) degree of stromal cellularity, (ii) stromal cytological atypia, (iii) mitotic activity, (iv) stromal overgrowth, and (v) the type of tumor margins (infiltrating/pushing).…”